These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases. Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551 [TBL] [Abstract][Full Text] [Related]
5. Entropy increases from different sources support the high-affinity binding of the N-terminal inhibitory domains of tissue inhibitors of metalloproteinases to the catalytic domains of matrix metalloproteinases-1 and -3. Wu Y; Wei S; Van Doren SR; Brew K J Biol Chem; 2011 May; 286(19):16891-9. PubMed ID: 21454617 [TBL] [Abstract][Full Text] [Related]
6. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Gonnella NC; Li YC; Zhang X; Paris CG Bioorg Med Chem; 1997 Dec; 5(12):2193-201. PubMed ID: 9459017 [TBL] [Abstract][Full Text] [Related]
7. Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Li YC; Zhang X; Melton R; Ganu V; Gonnella NC Biochemistry; 1998 Oct; 37(40):14048-56. PubMed ID: 9760240 [TBL] [Abstract][Full Text] [Related]
8. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin. Dunten P; Kammlott U; Crowther R; Levin W; Foley LH; Wang P; Palermo R Protein Sci; 2001 May; 10(5):923-6. PubMed ID: 11316871 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements. Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939 [TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835 [TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812 [TBL] [Abstract][Full Text] [Related]
14. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases. Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004 [TBL] [Abstract][Full Text] [Related]
15. pH stability of the stromelysin-1 catalytic domain and its mechanism of interaction with a glyoxal inhibitor. Howe N; Ceruso M; Spink E; Malthouse JP Biochim Biophys Acta; 2011 Oct; 1814(10):1394-403. PubMed ID: 21782982 [TBL] [Abstract][Full Text] [Related]
16. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Dhanaraj V; Ye QZ; Johnson LL; Hupe DJ; Ortwine DF; Dunbar JB; Rubin JR; Pavlovsky A; Humblet C; Blundell TL Structure; 1996 Apr; 4(4):375-86. PubMed ID: 8740360 [TBL] [Abstract][Full Text] [Related]
17. Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics. Hou T; Zhang W; Xu X J Comput Aided Mol Des; 2002 Jan; 16(1):27-41. PubMed ID: 12197664 [TBL] [Abstract][Full Text] [Related]
18. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Pavlovsky AG; Williams MG; Ye QZ; Ortwine DF; Purchase CF; White AD; Dhanaraj V; Roth BD; Johnson LL; Hupe D; Humblet C; Blundell TL Protein Sci; 1999 Jul; 8(7):1455-62. PubMed ID: 10422833 [TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase inhibitors: a structure-activity study. Levy DE; Lapierre F; Liang W; Ye W; Lange CW; Li X; Grobelny D; Casabonne M; Tyrrell D; Holme K; Nadzan A; Galardy RE J Med Chem; 1998 Jan; 41(2):199-223. PubMed ID: 9457244 [TBL] [Abstract][Full Text] [Related]
20. The constituent tryptophans and bisANS as fluorescent probes of the active site and of a secondary binding site of stromelysin-1 (MMP-3). Epps DE; Poorman RA; Petzold GL; Stuchly CW; Laborde AL; Van Drie JH J Protein Chem; 1998 Oct; 17(7):699-712. PubMed ID: 9853686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]